Covered recipient · General Payments record
SARAH YUE WANG
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$10,235.95
86 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,040.00 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,632.00 | 1 |
| Food and Beverage | $2,563.95 | 81 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SARAH YUE WANG
NPI 1841581931 · CMS profile ID 3670781
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
TYLER, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1841581931?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SARAH YUE WANG, NPI 1841581931, CMS profile ID 3670781. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841581931?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). SARAH YUE WANG, NPI 1841581931, CMS profile ID 3670781. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841581931?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- SARAH YUE WANG, NPI 1841581931, CMS profile ID 3670781, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1841581931?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
86 matching records · $10,235.95 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–86 of 86.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $27.21 | 06/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206427142 | CMS |
| Tempus AI, Inc | $19.98 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250353130 | CMS |
| Daiichi Sankyo Inc. | $25.66 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197079341 | CMS |
| Daiichi Sankyo Inc. | $33.13 | 05/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197083839 | CMS |
| PFIZER INC. | $25.03 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230504974 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.21 | 05/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207009239 | CMS |
| SOBI, INC | $21.22 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240278439 | CMS |
| Janssen Biotech, Inc. | $31.86 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175168463 | CMS |
| Novartis Pharmaceuticals Corporation | $20.84 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200565819 | CMS |
| Novartis Pharmaceuticals Corporation | $14.14 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200565821 | CMS |
| Karyopharm Therapeutics Inc. | $15.86 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246651815 | CMS |
| Tempus AI, Inc | $27.66 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250353128 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.70 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184563703 | CMS |
| Celgene Corporation | $35.00 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184563695 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $187.66 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181725933 | CMS |
| ARRAY BIOPHARMA INC | $18.14 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230495785 | CMS |
| Lilly USA, LLC | $14.28 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186885923 | CMS |
| Janssen Biotech, Inc. | $17.22 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175168414 | CMS |
| Daiichi Sankyo Inc. | $113.33 | 04/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197057853 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.43 | 04/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206833879 | CMS |
| Daiichi Sankyo Inc. | $22.64 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197059287 | CMS |
| Tempus AI, Inc | $19.96 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250353126 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.16 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206527808 | CMS |
| Stemline Therapeutics Inc. | $19.20 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244106107 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.94 | 03/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206638985 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.51 | 02/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184563683 | CMS |
| AstraZeneca Pharmaceuticals LP | $28.27 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206239271 | CMS |
| Geron Corporation | $24.41 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238895855 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.63 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206306033 | CMS |
| Tempus AI, Inc | $19.84 | 02/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250353124 | CMS |
| Daiichi Sankyo Inc. | $1,110.00 | 02/13/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197029185 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $15.10 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225885601 | CMS |
| Tempus AI, Inc | $6.00 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250353122 | CMS |
| Helsinn Therapeutics (U.S.), Inc. | $22.27 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186334885 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.68 | 01/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206546885 | CMS |
| Tempus AI, Inc | $8.69 | 01/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250353120 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $389,738.51 | 117 |
| PY2024 | Principal investigator | $19,970.99 | 3 |
| PY2023 | Principal investigator | $294,160.74 | 6 |
| PY2022 | Principal investigator | $460,308.91 | 19 |
| PY2021 | Principal investigator | $214,964.44 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
117 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $564.36 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | KEYMAKER-U01 Substudy 01E# A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II IIIB N2 Non-small Cell | No dispute reported | 06/30/2026 | 1232924999 |
| Principal investigator 1 | Amgen Inc. | $51,500.00 | 12/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTION LLC | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | No dispute reported | 06/30/2026 | 1246647913 |
| Principal investigator 1 | Amgen Inc. | $28,600.00 | 12/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTION LLC | A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1246647963 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $123.00 | 12/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382072 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $116.00 | 12/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382100 |
| Principal investigator 1 | ABBVIE INC. | $2,292.30 | 12/04/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202527316 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328052 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382070 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382078 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382088 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382092 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,166.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382096 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 11/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382098 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,000.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175329458 |
| Principal investigator 1 | ABBVIE INC. | $2,292.30 | 11/05/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202523137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,316.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382074 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,193.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382076 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382080 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,193.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382082 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,316.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382094 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,193.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382104 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,193.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382106 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,512.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382108 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 10/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382084 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 10/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382086 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,175.00 | 10/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382090 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 10/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382102 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 10/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382110 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,839.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382044 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,388.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382068 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,000.00 | 09/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382030 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15,000.00 | 09/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382032 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382036 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $570.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382038 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382040 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,051.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382042 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 09/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382062 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,900.00 | 09/10/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382034 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,500.00 | 09/10/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382064 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,500.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382046 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,000.00 | 09/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382048 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385285 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385287 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385289 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385291 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385293 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385295 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385297 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385299 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385301 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385303 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385305 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385307 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,130.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382050 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,291.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382052 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,291.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382054 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,928.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382056 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,928.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382058 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,549.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382060 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,644.00 | 08/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | DS7300-188 | No dispute reported | 06/30/2026 | 1223382066 |
| Principal investigator 1 | ABBVIE INC. | $19,000.00 | 05/07/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202482765 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $107,934.34 | 05/06/2025 | Non-covered Recipient Entity Texas Oncology Tyler | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235993209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.25 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385045 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.15 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385047 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.15 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385049 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.15 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385051 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385053 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385055 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385057 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385059 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385061 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385063 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $91.25 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385065 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385067 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.25 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385069 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385071 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $91.25 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385073 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385075 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385077 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385079 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.30 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385081 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.30 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385083 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.30 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385085 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $75.00 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385087 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $75.00 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385089 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $154.65 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385091 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $154.65 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385093 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $154.65 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385095 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $44.70 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385097 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385099 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385101 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385103 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385105 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385107 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385109 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385111 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385113 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385115 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.25 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385117 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.80 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385119 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $29.25 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385121 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $29.25 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385123 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.80 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385125 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $29.25 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385127 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385129 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385131 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $44.70 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385133 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $91.25 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385135 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $75.00 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385139 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.80 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385141 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $44.70 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385143 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/11/2025 | Non-covered Recipient Entity Texas Oncology - Northeast Texas | DS7300-188 | No dispute reported | 06/30/2026 | 1223385145 |
| Principal investigator 1 | Amgen Inc. | $9,000.00 | 02/28/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY NORTHEAST TEXAS | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | No dispute reported | 06/30/2026 | 1246649301 |
| Principal investigator 1 | Amgen Inc. | $16,697.52 | 02/25/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY NORTHEAST TEXAS | A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1246649305 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $588.64 | 02/25/2025 | Non-covered Recipient Entity Texas Oncology Tyler | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235993211 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,500.00 | 02/21/2025 | Covered Recipient Teaching Hospital Parkview Hospital | A Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participants with treatment-na ve, metastatic nonsmall cell lung cancer NSCLC whose tumors have a tumor proportion score TPS greater tha | No dispute reported | 06/30/2026 | 1232936788 |